世界の家族性アミロイド多発ニューロパチー治療市場インサイト及び予測(イノテルセン、タファミディス、パティシラン、その他)

【英語タイトル】Global Familial Amyloid Polyneuropathy Therapeutic Market Insights, Forecast to 2028

QYResearchが出版した調査資料(QY22DE19036)・商品コード:QY22DE19036
・発行会社(調査会社):QYResearch
・発行日:2022年12月
・ページ数:94
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後3営業日)
・調査対象地域:グローバル
・産業分野:医薬品&医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

COVID-19パンデミックとロシア・ウクライナ戦争の影響により、家族性アミロイド多発ニューロパチー治療の世界市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
家族性アミロイド多発ニューロパチー治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
家族性アミロイド多発ニューロパチー治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
家族性アミロイド多発ニューロパチー治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面に関しては、当レポートは2017年から2022年までの家族性アミロイド多発ニューロパチー治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面に関しては、当レポートは2017年から2022年までの地域別、企業別、種類別、用途別の家族性アミロイド多発ニューロパチー治療の売上および2028年までの予測に焦点を当てています。

家族性アミロイド多発ニューロパチー治療のグローバル主要企業には、Pfizer Inc.、Alnylam Pharmaceuticals Inc.、Ionis Pharmaceuticals Inc.、Corino Therapeutics Inc.、Proclara Biosciences、Arcturus Therapeutics Incなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

家族性アミロイド多発ニューロパチー治療市場は、種類と用途によって区分されます。世界の家族性アミロイド多発ニューロパチー治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
イノテルセン、タファミディス、パティシラン、その他

【用途別セグメント】
病院薬局、小売薬局、オンライン薬局、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 家族性アミロイド多発ニューロパチー治療製品概要
- 種類別市場(イノテルセン、タファミディス、パティシラン、その他)
- 用途別市場(病院薬局、小売薬局、オンライン薬局、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界の家族性アミロイド多発ニューロパチー治療販売量予測2017-2028
- 世界の家族性アミロイド多発ニューロパチー治療売上予測2017-2028
- 家族性アミロイド多発ニューロパチー治療の地域別販売量
- 家族性アミロイド多発ニューロパチー治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別家族性アミロイド多発ニューロパチー治療販売量
- 主要メーカー別家族性アミロイド多発ニューロパチー治療売上
- 主要メーカー別家族性アミロイド多発ニューロパチー治療価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(イノテルセン、タファミディス、パティシラン、その他)
- 家族性アミロイド多発ニューロパチー治療の種類別販売量
- 家族性アミロイド多発ニューロパチー治療の種類別売上
- 家族性アミロイド多発ニューロパチー治療の種類別価格
・用途別市場規模(病院薬局、小売薬局、オンライン薬局、その他)
- 家族性アミロイド多発ニューロパチー治療の用途別販売量
- 家族性アミロイド多発ニューロパチー治療の用途別売上
- 家族性アミロイド多発ニューロパチー治療の用途別価格
・北米市場
- 北米の家族性アミロイド多発ニューロパチー治療市場規模(種類別、用途別)
- 主要国別の家族性アミロイド多発ニューロパチー治療市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの家族性アミロイド多発ニューロパチー治療市場規模(種類別、用途別)
- 主要国別の家族性アミロイド多発ニューロパチー治療市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の家族性アミロイド多発ニューロパチー治療市場規模(種類別、用途別)
- 主要国別の家族性アミロイド多発ニューロパチー治療市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の家族性アミロイド多発ニューロパチー治療市場規模(種類別、用途別)
- 主要国別の家族性アミロイド多発ニューロパチー治療市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの家族性アミロイド多発ニューロパチー治療市場規模(種類別、用途別)
- 主要国別の家族性アミロイド多発ニューロパチー治療市場規模(トルコ、サウジアラビア)
・企業情報
Pfizer Inc.、Alnylam Pharmaceuticals Inc.、Ionis Pharmaceuticals Inc.、Corino Therapeutics Inc.、Proclara Biosciences、Arcturus Therapeutics Inc
・産業チェーン及び販売チャネル分析
- 家族性アミロイド多発ニューロパチー治療の産業チェーン分析
- 家族性アミロイド多発ニューロパチー治療の原材料
- 家族性アミロイド多発ニューロパチー治療の生産プロセス
- 家族性アミロイド多発ニューロパチー治療の販売及びマーケティング
- 家族性アミロイド多発ニューロパチー治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 家族性アミロイド多発ニューロパチー治療の産業動向
- 家族性アミロイド多発ニューロパチー治療のマーケットドライバー
- 家族性アミロイド多発ニューロパチー治療の課題
- 家族性アミロイド多発ニューロパチー治療の阻害要因
・主な調査結果

Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).
Report Overview
Due to the COVID-19 pandemic and Russia-Ukraine War Influence, the global market for Familial Amyloid Polyneuropathy Therapeutic estimated at US$ million in the year 2022, is projected to reach a revised size of US$ million by 2028, growing at a CAGR of % during the forecast period 2022-2028.
The USA market for Familial Amyloid Polyneuropathy Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The China market for Familial Amyloid Polyneuropathy Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The Europe market for Familial Amyloid Polyneuropathy Therapeutic is estimated to increase from $ million in 2022 to reach $ million by 2028, at a CAGR of % during the forecast period of 2023 through 2028.
The global key companies of Familial Amyloid Polyneuropathy Therapeutic include Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences and Arcturus Therapeutics Inc, etc. In 2021, the global top five players had a share approximately % in terms of revenue.
Report Scope
This latest report researches the industry structure, revenue and gross margin. Major players’ headquarters, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Familial Amyloid Polyneuropathy Therapeutic companies, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.
This report also includes a discussion of the major players across each regional Familial Amyloid Polyneuropathy Therapeutic market. Further, it explains the major drivers and regional dynamics of the global Familial Amyloid Polyneuropathy Therapeutic market and current trends within the industry.
Key Companies Covered
In this section of the report, the researchers have done a comprehensive analysis of the prominent players operating and the strategies they are focusing on to combat the intense competition. Company profiles and market share analysis of the prominent players are also provided in this section. Additionally, the specialists have done an all-encompassing analysis of each player. They have also provided reliable revenue, market share and rank data of the companies for the period 2017-2022. With the assistance of this report, key players, stakeholders, and other participants will be able to stay abreast of the recent and upcoming developments in the business, further enabling them to make efficient choices. Mentioned below are the prime players taken into account in this research report:
Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc
Market Segments
This report has explored the key segments: by Drug Type and by Application. The lucrativeness and growth potential have been looked into by the industry experts in this report. This report also provides revenue forecast data by drug type and by application segments based on value for the period 2017-2028.
Familial Amyloid Polyneuropathy Therapeutic Segment by Drug Type
Inotersen
Tafamidis
Patisiran
Others
Familial Amyloid Polyneuropathy Therapeutic Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others
Key Regions & Countries
This section of the report provides key insights regarding various regions and the key players operating in each region. Economic, social, environmental, technological, and political factors have been taken into consideration while assessing the growth of the particular region/country. The readers will also get their hands on the value data of each region and country for the period 2017-2028.
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
COVID-19 and Russia-Ukraine War Influence Analysis
The readers in the section will understand how the Familial Amyloid Polyneuropathy Therapeutic market scenario changed across the globe during the pandemic, post-pandemic and Russia-Ukraine War. The study is done keeping in view the changes in aspects such as demand, consumption, transportation, consumer behavior, supply chain management, export and import, and production. The industry experts have also highlighted the key factors that will help create opportunities for players and stabilize the overall industry in the years to come.
Report Includes:
This report presents an overview of global market for Familial Amyloid Polyneuropathy Therapeutic market size. Analyses of the global market trends, with historic market revenue data for 2017 – 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Familial Amyloid Polyneuropathy Therapeutic, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Familial Amyloid Polyneuropathy Therapeutic, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Familial Amyloid Polyneuropathy Therapeutic revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Familial Amyloid Polyneuropathy Therapeutic market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Familial Amyloid Polyneuropathy Therapeutic revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences and Arcturus Therapeutics Inc, etc.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Familial Amyloid Polyneuropathy Therapeutic in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Familial Amyloid Polyneuropathy Therapeutic companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments according to product types, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments according to application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by drug type, by application and by country, revenue for each segment.
Chapter 7: Europe by drug type, by application and by country, revenue for each segment.
Chapter 8: Asia Pacific by drug type, by application and by country/region, revenue for each segment.
Chapter 9: Latin America by drug type, by application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by drug type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Familial Amyloid Polyneuropathy Therapeutic revenue, gross margin, and recent development, etc.
Chapter 12: Analyst’s Viewpoints/Conclusions

❖ レポートの目次 ❖

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Drug Type
1.2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Drug Type, 2017 VS 2021 VS 2028
1.2.2 Inotersen
1.2.3 Tafamidis
1.2.4 Patisiran
1.2.5 Others
1.3 Market by Application
1.3.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Perspective (2017-2028)
2.2 Familial Amyloid Polyneuropathy Therapeutic Growth Trends by Region
2.2.1 Familial Amyloid Polyneuropathy Therapeutic Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Region (2017-2022)
2.2.3 Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2023-2028)
2.3 Familial Amyloid Polyneuropathy Therapeutic Market Dynamics
2.3.1 Familial Amyloid Polyneuropathy Therapeutic Industry Trends
2.3.2 Familial Amyloid Polyneuropathy Therapeutic Market Drivers
2.3.3 Familial Amyloid Polyneuropathy Therapeutic Market Challenges
2.3.4 Familial Amyloid Polyneuropathy Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Revenue
3.1.1 Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Revenue (2017-2022)
3.1.2 Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Players (2017-2022)
3.2 Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Familial Amyloid Polyneuropathy Therapeutic Revenue
3.4 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio
3.4.1 Global Familial Amyloid Polyneuropathy Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2021
3.5 Familial Amyloid Polyneuropathy Therapeutic Key Players Head office and Area Served
3.6 Key Players Familial Amyloid Polyneuropathy Therapeutic Product Solution and Service
3.7 Date of Enter into Familial Amyloid Polyneuropathy Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Drug Type
4.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Drug Type (2017-2022)
4.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Drug Type (2023-2028)
5 Familial Amyloid Polyneuropathy Therapeutic Breakdown Data by Application
5.1 Global Familial Amyloid Polyneuropathy Therapeutic Historic Market Size by Application (2017-2022)
5.2 Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
6.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type
6.2.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022)
6.2.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028)
6.2.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Drug Type (2017-2028)
6.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
6.3.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022)
6.3.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028)
6.3.3 North America Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2017-2028)
6.4 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
6.4.1 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
6.4.2 North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
7.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type
7.2.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022)
7.2.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028)
7.2.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Drug Type (2017-2028)
7.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
7.3.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022)
7.3.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028)
7.3.3 Europe Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2017-2028)
7.4 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
7.4.1 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
7.4.2 Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
8.2 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type
8.2.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022)
8.2.2 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028)
8.2.3 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Share by Drug Type (2017-2028)
8.3 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
8.3.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2017-2028)
8.4 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region
8.4.1 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
9.2 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type
9.2.1 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022)
9.2.2 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028)
9.2.3 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Drug Type (2017-2028)
9.3 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
9.3.1 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022)
9.3.2 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028)
9.3.3 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2017-2028)
9.4 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
9.4.1 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
9.4.2 Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size (2017-2028)
10.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type
10.2.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022)
10.2.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028)
10.2.3 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Share by Drug Type (2017-2028)
10.3 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Application
10.3.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Share by Application (2017-2028)
10.4 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country
10.4.1 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Pfizer Inc.
11.1.1 Pfizer Inc. Company Details
11.1.2 Pfizer Inc. Business Overview
11.1.3 Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.1.4 Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.1.5 Pfizer Inc. Recent Developments
11.2 Alnylam Pharmaceuticals Inc.
11.2.1 Alnylam Pharmaceuticals Inc. Company Details
11.2.2 Alnylam Pharmaceuticals Inc. Business Overview
11.2.3 Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.2.4 Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.2.5 Alnylam Pharmaceuticals Inc. Recent Developments
11.3 Ionis Pharmaceuticals Inc.
11.3.1 Ionis Pharmaceuticals Inc. Company Details
11.3.2 Ionis Pharmaceuticals Inc. Business Overview
11.3.3 Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.3.4 Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.3.5 Ionis Pharmaceuticals Inc. Recent Developments
11.4 Corino Therapeutics Inc.
11.4.1 Corino Therapeutics Inc. Company Details
11.4.2 Corino Therapeutics Inc. Business Overview
11.4.3 Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Introduction
11.4.4 Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.4.5 Corino Therapeutics Inc. Recent Developments
11.5 Proclara Biosciences
11.5.1 Proclara Biosciences Company Details
11.5.2 Proclara Biosciences Business Overview
11.5.3 Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Introduction
11.5.4 Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.5.5 Proclara Biosciences Recent Developments
11.6 Arcturus Therapeutics Inc
11.6.1 Arcturus Therapeutics Inc Company Details
11.6.2 Arcturus Therapeutics Inc Business Overview
11.6.3 Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Introduction
11.6.4 Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
11.6.5 Arcturus Therapeutics Inc Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer

List of Tables
Table 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Drug Type (US$ Million), 2017 VS 2021 VS 2028
Table 2. Key Players of Inotersen
Table 3. Key Players of Tafamidis
Table 4. Key Players of Patisiran
Table 5. Key Players of Others
Table 6. Global Familial Amyloid Polyneuropathy Therapeutic Market Size Growth Rate by Application (US$ Million), 2017 VS 2021 VS 2028
Table 7. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 8. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2017-2022) & (US$ Million)
Table 9. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2017-2022)
Table 10. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 11. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region (2023-2028)
Table 12. Familial Amyloid Polyneuropathy Therapeutic Market Trends
Table 13. Familial Amyloid Polyneuropathy Therapeutic Market Drivers
Table 14. Familial Amyloid Polyneuropathy Therapeutic Market Challenges
Table 15. Familial Amyloid Polyneuropathy Therapeutic Market Restraints
Table 16. Global Familial Amyloid Polyneuropathy Therapeutic Revenue by Players (2017-2022) & (US$ Million)
Table 17. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Players (2017-2022)
Table 18. Global Top Familial Amyloid Polyneuropathy Therapeutic by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2021)
Table 19. Ranking of Global Top Familial Amyloid Polyneuropathy Therapeutic Companies by Revenue (US$ Million) in 2021
Table 20. Global 5 Largest Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue (CR5 and HHI) & (2017-2022)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Familial Amyloid Polyneuropathy Therapeutic Product Solution and Service
Table 23. Date of Enter into Familial Amyloid Polyneuropathy Therapeutic Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & (US$ Million)
Table 26. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Drug Type (2017-2022)
Table 27. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Drug Type (2023-2028) & (US$ Million)
Table 28. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Market Share by Drug Type (2023-2028)
Table 29. Global Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & (US$ Million)
Table 30. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Application (2017-2022)
Table 31. Global Familial Amyloid Polyneuropathy Therapeutic Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 32. Global Familial Amyloid Polyneuropathy Therapeutic Revenue Share by Application (2023-2028)
Table 33. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & (US$ Million)
Table 34. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028) & (US$ Million)
Table 35. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & (US$ Million)
Table 36. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028) & (US$ Million)
Table 37. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & (US$ Million)
Table 38. North America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028) & (US$ Million)
Table 39. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & (US$ Million)
Table 40. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028) & (US$ Million)
Table 41. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & (US$ Million)
Table 42. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028) & (US$ Million)
Table 43. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & (US$ Million)
Table 44. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028) & (US$ Million)
Table 45. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & (US$ Million)
Table 46. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028) & (US$ Million)
Table 47. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & (US$ Million)
Table 48. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028) & (US$ Million)
Table 49. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2017-2022) & (US$ Million)
Table 50. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size by Region (2023-2028) & (US$ Million)
Table 51. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & (US$ Million)
Table 52. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028) & (US$ Million)
Table 53. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & (US$ Million)
Table 54. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028) & (US$ Million)
Table 55. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & (US$ Million)
Table 56. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028) & (US$ Million)
Table 57. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2017-2022) & (US$ Million)
Table 58. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Drug Type (2023-2028) & (US$ Million)
Table 59. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2017-2022) & (US$ Million)
Table 60. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Application (2023-2028) & (US$ Million)
Table 61. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2017-2022) & (US$ Million)
Table 62. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size by Country (2023-2028) & (US$ Million)
Table 63. Pfizer Inc. Company Details
Table 64. Pfizer Inc. Business Overview
Table 65. Pfizer Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 66. Pfizer Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
Table 67. Pfizer Inc. Recent Developments
Table 68. Alnylam Pharmaceuticals Inc. Company Details
Table 69. Alnylam Pharmaceuticals Inc. Business Overview
Table 70. Alnylam Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 71. Alnylam Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
Table 72. Alnylam Pharmaceuticals Inc. Recent Developments
Table 73. Ionis Pharmaceuticals Inc. Company Details
Table 74. Ionis Pharmaceuticals Inc. Business Overview
Table 75. Ionis Pharmaceuticals Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 76. Ionis Pharmaceuticals Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
Table 77. Ionis Pharmaceuticals Inc. Recent Developments
Table 78. Corino Therapeutics Inc. Company Details
Table 79. Corino Therapeutics Inc. Business Overview
Table 80. Corino Therapeutics Inc. Familial Amyloid Polyneuropathy Therapeutic Product
Table 81. Corino Therapeutics Inc. Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
Table 82. Corino Therapeutics Inc. Recent Developments
Table 83. Proclara Biosciences Company Details
Table 84. Proclara Biosciences Business Overview
Table 85. Proclara Biosciences Familial Amyloid Polyneuropathy Therapeutic Product
Table 86. Proclara Biosciences Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
Table 87. Proclara Biosciences Recent Developments
Table 88. Arcturus Therapeutics Inc Company Details
Table 89. Arcturus Therapeutics Inc Business Overview
Table 90. Arcturus Therapeutics Inc Familial Amyloid Polyneuropathy Therapeutic Product
Table 91. Arcturus Therapeutics Inc Revenue in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022) & (US$ Million)
Table 92. Arcturus Therapeutics Inc Recent Developments
Table 93. Research Programs/Design for This Report
Table 94. Key Data Information from Secondary Sources
Table 95. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Drug Type: 2021 VS 2028
Figure 2. Inotersen Features
Figure 3. Tafamidis Features
Figure 4. Patisiran Features
Figure 5. Others Features
Figure 6. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Application: 2021 VS 2028
Figure 7. Hospital Pharmacies Case Studies
Figure 8. Retail Pharmacies Case Studies
Figure 9. Online Pharmacies Case Studies
Figure 10. Others Case Studies
Figure 11. Familial Amyloid Polyneuropathy Therapeutic Report Years Considered
Figure 12. Global Familial Amyloid Polyneuropathy Therapeutic Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 13. Global Familial Amyloid Polyneuropathy Therapeutic Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 14. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Region: 2021 VS 2028
Figure 15. Global Familial Amyloid Polyneuropathy Therapeutic Market Share by Players in 2021
Figure 16. Global Top Familial Amyloid Polyneuropathy Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Familial Amyloid Polyneuropathy Therapeutic as of 2021)
Figure 17. The Top 10 and 5 Players Market Share by Familial Amyloid Polyneuropathy Therapeutic Revenue in 2021
Figure 18. North America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY (2017-2028) & (US$ Million)
Figure 19. North America Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2028)
Figure 20. North America Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2028)
Figure 21. North America Familial Amyloid Polyneuropathy Therapeutic Market Size Share by Country (2017-2028)
Figure 22. United States Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. Canada Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 24. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size YoY (2017-2028) & (US$ Million)
Figure 25. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2028)
Figure 26. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2028)
Figure 27. Europe Familial Amyloid Polyneuropathy Therapeutic Market Size Share by Country (2017-2028)
Figure 28. Germany Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size YoY (2017-2028) & (US$ Million)
Figure 35. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2028)
Figure 36. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2028)
Figure 37. Asia Pacific Familial Amyloid Polyneuropathy Therapeutic Market Size Share by Region (2017-2028)
Figure 38. China Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Japan Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. South Korea Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Southeast Asia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. India Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Australia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 44. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size YoY (2017-2028) & (US$ Million)
Figure 45. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2028)
Figure 46. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2028)
Figure 47. Latin America Familial Amyloid Polyneuropathy Therapeutic Market Size Share by Country (2017-2028)
Figure 48. Mexico Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Brazil Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Middle East & Africa Familial Amyloid Polyneuropathy Therapeutic Market Size YoY (2017-2028) & (US$ Million)
Figure 51. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Drug Type (2017-2028)
Figure 52. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Market Share by Application (2017-2028)
Figure 53. Middle East and Africa Familial Amyloid Polyneuropathy Therapeutic Market Size Share by Country (2017-2028)
Figure 54. Turkey Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 55. Saudi Arabia Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 56. UAE Familial Amyloid Polyneuropathy Therapeutic Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 57. Pfizer Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
Figure 58. Alnylam Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
Figure 59. Ionis Pharmaceuticals Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
Figure 60. Corino Therapeutics Inc. Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
Figure 61. Proclara Biosciences Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
Figure 62. Arcturus Therapeutics Inc Revenue Growth Rate in Familial Amyloid Polyneuropathy Therapeutic Business (2017-2022)
Figure 63. Bottom-up and Top-down Approaches for This Report
Figure 64. Data Triangulation
Figure 65. Key Executives Interviewed


★調査レポート[世界の家族性アミロイド多発ニューロパチー治療市場インサイト及び予測(イノテルセン、タファミディス、パティシラン、その他)] (コード:QY22DE19036)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の家族性アミロイド多発ニューロパチー治療市場インサイト及び予測(イノテルセン、タファミディス、パティシラン、その他)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆